<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03175835</url>
  </required_header>
  <id_info>
    <org_study_id>148DDI16023</org_study_id>
    <nct_id>NCT03175835</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Multiple Dose, Fixed-sequence, 3-period Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug interaction between CKD-519 and
      rosuvastatin in healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, multiple dose, fixed-sequence, 3-period study to evaluate the drug interaction
      between CKD-519 and rosuvastatin in healthy male subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">June 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Area under the plasma concentration versus time curve (AUCτ))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Peak plasma Concentration (Cmax,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Minimum plasma Concentration (Cmin,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Time to maximum plasma concentration (Tmax,ss))</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (t1/2)</measure>
    <time_frame>0(predose)~24 hours at Day1, Day3, Day4, Day5, Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (CETP activity)</measure>
    <time_frame>0(predose)~24 hours at Day9, Day12, Day15, Day17, Day18, Day19, Day22, Day24, Day25, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (CETP Concentration)</measure>
    <time_frame>0(predose)~24 hours at Day9, Day19, Day22, Day26</time_frame>
    <description>At steady state after multiple administration of CKD-519, Rosuvastatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (Lipid profiles)</measure>
    <time_frame>simultaneous with laboratory test at Day1, Day6, Day9, Day20, Day22, Day27</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))
Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))
Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg</intervention_name>
    <description>Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>Rosuvastatin 20 mg(20 mg X 1 tablet)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519 200 mg</intervention_name>
    <description>Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>CKD-519 200 mg(100 mg X 2 tablets)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg &amp; CKD-519 200 mg</intervention_name>
    <description>Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26</description>
    <arm_group_label>Rosuvastatin 20 mg &amp; CKD-519 200 mg</arm_group_label>
    <other_name>Rosuvastatin 20 mg(20 mgX1 tablet), CKD-519 200 mg(100 mgX2 tablets)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥ 20 and ≤ 45 years old

          2. Weight ≥ 50kg, with calculated body mass index(BMI) of ≥ 18 and ≤ 29.9kg/m²

          3. Subjects to consents to use effective birth controls for at least 2 months following
             the last dose

          4. Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and comply with the relevant instructions in written

        Exclusion Criteria:

          1. History or presence of clinically significant and active cardiovascular, respiratory,
             hepatobiliary, renal, endocrine, hematological, gastrointestinal, neurologic, immune,
             dermatologic or psychiatric disorder

          2. With symptoms indicating acute illness within 28 days prior to the first
             Investigational Product administration

          3. Any medical history that may affect drug absorption, distribution, metabolism and
             excretion

          4. Any hypersensitivity reaction or clinically significant hypersensitivity reaction in
             the history of statin-related medication or Cholesteryl Ester Transfer Protein(CETP)
             inhibitor or other drugs(aspirin, antibiotics)

          5. Continuous cryptogenic elevation of serum transaminase or active liver disease
             including elevation of serum transaminase &gt; 3 fold upper normal limit(UNL)

          6. Severe renal failure(creatinin clearance &lt; 30 ml/min)

          7. Hypothyroidism or clinically significant test result

          8. Galactose intolerance, Lapp lactose intolerance, glucose-galactose malabsorption or
             genetic disorders

          9. Any clinically significant chronic medical illness

         10. Any clinically significant hypotension or hypertension (systolic &lt; 100 mmHg/diastolic
             &lt; 60 mmHg or systolic &gt; 140 mmHg /diastolic &gt; 90 mmHg)

         11. Corrected QT interval(QTc) &gt;450msec on 12-lead ECG

         12. Positive blood tests for hemoglobins(HBs) Ag, anti-hepatitis C virus(HCV) Ab, anti-HIV
             Ab, or venereal disease research laboratory(VDRL)

         13. Creatine phosphokinase(CPK) ≥ 5 fold of upper normal limit(UNL)

         14. Use of any prescription drugs within 14 days prior to study drug administration

         15. Use of any other drugs, including over-the-counter medications and herbal preparations
             within 7 days prior to study drug administration

         16. History of clinically significant allergic reaction (However, mild allergic rhinitis
             or allergic dermatitis which do not require any treatment may be allowed)

         17. Inability to take normal hospital diet

         18. Donation of blood within 60 days prior to study drug administration or plasma to a
             blood bank within 20 days prior to study drug administration

         19. Blood transfusion within 30 days prior to study drug administration

         20. Exposure to any investigational drug or placebo within 90 days prior to the first
             Investigational Product(IP) administration

         21. Subjects taking any drugs to induce or inhibit drug metabolizing enzymes including
             barbiturates within 30 days prior to the first Investigational Product(IP)
             administration

         22. Subjects with excessive caffeine intake (more than 5 cups/day), heavy smoking (more
             than 10 cigarettes/day), regular alcohol intake (more than 210 g/week)

         23. Subjects having been deemed inappropriate for the trial as determined by the
             investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>CKD-519</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

